Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
MRI-Guided Radiotherapy: Hype or Here to Stay?
share announcement

MRI-Guided Radiotherapy: Hype or Here to Stay?

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 November 2024 | Viewed by 805

Special Issue Editors

Dr. Sweet Ping Ng

E-Mail Website
Guest Editor
Department of Radiation Oncology, Austin Health, Melbourne, VIC 3004, Australia
Interests: radiation oncology; MRI; adaptive radiotherapy; precision oncology
Dr. Michael G. Jameson

E-Mail Website
Guest Editor
GenesisCare, St Vincent’s Hospital, Sydney 2010, Australia
Interests: medical physics; radiation oncology; MRI; dosimetry; adaptive radiotherapy

Special Issue Information

Dear Colleagues,

Magnetic-resonance-imaging-guided radiotherapy has been growing in recent years. This initially started with the use of MR imaging as secondary datasets from radiology in planning followed by dedicated MRI simulators in radiotherapy departments. The most recent development has been magnetic resonance linear accelerators that allow for MRI-guided online adaptive radiotherapy.

This Special Issue aims to provide up-to-date articles on the use of magnetic resonance imaging in radiation oncology.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Optimization of MR images for visualizing cancer, contouring and assessing treatment response;
  • Image registration;
  • Dose cumulation strategies;
  • Treatment planning;
  • Dedicated MR simulation;
  • MR-only planning;
  • MR-guided adaptive radiotherapy;
  • MR Linacs;
  • Quantitative and functional MRI for oncology.

We look forward to receiving your contributions.

Dr. Sweet Ping Ng
Dr. Michael G. Jameson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • magnetic resonance imaging
  • radiotherapy
  • MR-guided
  • planning
  • simulation
  • registration

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1285 KiB  
Article
Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation
by Vlatko Potkrajcic, Cihan Gani, Stefan Georg Fischer, Simon Boeke, Maximilian Niyazi, Daniela Thorwarth, Otilia Voigt, Moritz Schneider, David Mönnich, Sarah Kübler, Jessica Boldt, Elgin Hoffmann, Frank Paulsen, Arndt-Christian Mueller and Daniel Wegener
Curr. Oncol. 2024, 31(5), 2679-2688; https://doi.org/10.3390/curroncol31050203 - 9 May 2024
Viewed by 435
Abstract
The use of hypofractionated radiotherapy in prostate cancer has been increasingly evaluated, whereas accumulated evidence demonstrates comparable oncologic outcomes and toxicity rates compared to normofractionated radiotherapy. In this prospective study, we evaluate all patients with intermediate-risk prostate cancer treated with ultrahypofractionated (UHF) MRI-guided [...] Read more.
The use of hypofractionated radiotherapy in prostate cancer has been increasingly evaluated, whereas accumulated evidence demonstrates comparable oncologic outcomes and toxicity rates compared to normofractionated radiotherapy. In this prospective study, we evaluate all patients with intermediate-risk prostate cancer treated with ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac within our department and report on workflow and feasibility, as well as physician-recorded and patient-reported longitudinal toxicity. A total of 23 patients with intermediate-risk prostate cancer treated on the 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions (seven MV step-and-shoot IMRT) were evaluated within the MRL-01 study (NCT04172753). The duration of each treatment step, choice of workflow (adapt to shape-ATS or adapt to position-ATP) and technical and/or patient-sided treatment failure were recorded for each fraction and patient. Acute and late toxicity were scored according to RTOG and CTC V4.0, as well as the use of patient-reported questionnaires. The median follow-up was 12.4 months. All patients completed the planned treatment. The mean duration of a treatment session was 38.2 min. In total, 165 radiotherapy fractions were delivered. ATS was performed in 150 fractions, 5 fractions were delivered using ATP, and 10 fractions were delivered using both ATS and ATP workflows. Severe acute bother (G3+) regarding IPS-score was reported in five patients (23%) at the end of radiotherapy. However, this tended to normalize and no G3+ IPS-score was observed later at any point during follow-up. Furthermore, no other severe genitourinary (GU) or gastrointestinal (GI) acute or late toxicity was observed. One-year biochemical-free recurrence survival was 100%. We report the excellent feasibility of UHF MR-guided radiotherapy for intermediate-risk prostate cancer patients and acceptable toxicity rates in our preliminary study. Randomized controlled studies with long-term follow-up are warranted to detect possible advantages over current state-of-the-art RT techniques. Full article
(This article belongs to the Special Issue MRI-Guided Radiotherapy: Hype or Here to Stay?)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop